Intraocular devices, systems, and methods

ChangeBridge: Patent Grants - Prosthetics (A61F)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12589025B2 to Sight Sciences, Inc. for intraocular implants configured to deliver drugs to the eye for treating eye conditions. The patent has 68 claims and names Paul Badawi, David Y. Badawi, and Daniel O'Keeffe as inventors. Filing date was May 27, 2022, with application number 17827573.

View original document View source feed page

What changed

USPTO granted Patent US12589025B2 to Sight Sciences, Inc. for intraocular implants designed to deliver drugs to eye structures including the posterior chamber (sulcus), iridocorneal angle, sclera, cornea, limbus, and vitreous. The patent contains 68 claims and was assigned CPC classifications A61F 9/0008, A61F 9/0017, and A61K 9/0051.

This is a routine patent grant notification with no compliance obligations or deadlines. Medical device manufacturers and pharmaceutical companies developing competing intraocular drug delivery systems should conduct freedom-to-operate analyses and consider potential licensing needs. The grant date is March 31, 2026.

Source document (simplified)

← USPTO Patent Grants

Intraocular devices, systems, and methods

Grant US12589025B2 Kind: B2 Mar 31, 2026

Assignee

SIGHT SCIENCES, INC.

Inventors

Paul Badawi, David Y. Badawi, Daniel O'Keeffe

Abstract

The present disclosure relates to intraocular implants for treating a condition of the eye, wherein the implant is configured to deliver a drug to the eye. The present disclosure also relates to methods of treating a condition of the eye by delivering a drug from intraocular implants to the posterior chamber (e.g., sulcus), iridocorneal angle, sclera, cornea, limbus, and vitreous.